Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
NCT07263594Phase 2Recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 2, open-label trial of DB-1324 in gastrointestinal cancer (4 arms), sponsored by Duality Biotherapeutics. Primary endpoints: Dose-Limiting Toxicities at 30 days, Serious Adverse Events at 30 days and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
DB-1324
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT07263594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263594.